![]() PF-04217903 phenolsulfonate structure
|
Common Name | PF-04217903 phenolsulfonate | ||
---|---|---|---|---|
CAS Number | 1159490-85-3 | Molecular Weight | 372.38300 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C25H22N8O5S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of PF-04217903 phenolsulfonatePF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2]. |
Name | 2-{4-[1-(6-Quinolinylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-y l]-1H-pyrazol-1-yl}ethanol |
---|
Description | PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2]. |
---|---|
Related Catalog | |
Target |
Ki: 4.8 nM (human c-Met)[1] |
In Vitro | PF-04217903 phenolsulfonate (0.1-10000 nM; 48-72 hours) inhibits proliferation of c-Met–amplified human GTL-16 gastric carcinoma and H1993 NSCLC cells with IC50 values of 12 and 30 nM, respectively[1]. PF-04217903 phenolsulfonate (1.5-3333 nM; 48 hours) induces apoptosis of GTL-16 cells (IC50=31 nM)[1]. PF-04217903 phenolsulfonate also inhibits HGF-mediated cell migration and Matrigel invasion in several c-Met–overexpressing tumor cell lines such as human NCI-H441 lung carcinoma and HT29 colon carcinoma with IC50 values comparable with those for inhibition of c-Met phosphorylation in these cell lines (IC50=7-12.5 nM)[1]. PF-04217903 phenolsulfonate displays similar potency to inhibit the activity of c-Met-H1094R, c-Met-R988C, and c-Met-T1010I with IC50 of 3.1 nM, 6.4 nM, and 6.7 nM, respectively. PF-04217903 phenolsulfonate has no inhibitory activity against c-Met-Y1230C with IC50 of >10 μM[3]. Cell Viability Assay[1] Cell Line: GTL-16, H1993 cells Concentration: 0.1, 1, 10, 100, 1000, 10000 nM Incubation Time: 48-72 hours Result: Inhibited proliferation of c-Met–amplified human GTL-16 gastric carcinoma and H1993 NSCLC cells with IC50 values of 12 and 30 nM, respectively. Apoptosis Analysis[1] Cell Line: GTL-16 cells Concentration: 1.5-3333 nM Incubation Time: 48 hours Result: Induced apoptosis of GTL-16 cells. |
In Vivo | PF-04217903 phenolsulfonate (1-30 mg/kg; p.o.; daily for 16 days) shows dose-dependent tumor growth inhibition, which correlated with the inhibition in c-Met phosphorylation in these tumors[1]. PF-04217903 phenolsulfonate (5-50 mg/kg, p.o.; once daily for 3 days) dose dependently inhibits c-Met, Gab-1, Erk1/2, and AKT phosphorylation and induced apoptosis (cleaved caspase-3) in U87MG xenograft tumors at all dose levels. PF-04217903 phenolsulfonate shows a significant dose-dependent reduction of human IL-8 levels in both the U87MG and GTL-16 models and decreases human VEGFA levels in the GTL-16 model. PF-04217903 phenolsulfonate strongly induces phospho-PDGFRβ levels in U87MG xenograft tumors[1]. Animal Model: Female nu/nu mice (GTL-16 xenograft model)[1] Dosage: 1, 3, 10, 30 mg/kg Administration: Oral; daily for 16 days Result: Showed dose-dependent tumor growth inhibition, and was correlated with the inhibition in c-Met phosphorylation in these tumors. |
References |
Molecular Formula | C25H22N8O5S |
---|---|
Molecular Weight | 372.38300 |
Exact Mass | 372.14500 |
PSA | 107.43000 |
LogP | 1.67360 |